News and Announcements
Xerion is pleased to announce the launch of their Pre-IPO funding round
- Published August 12, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Xerion is undertaking a Pre-IPO raising of $2.7M at $0.40 cents per share with an attaching 1:2 option at an exercise price of $0.50. These funds are to support a key asset purchase, targeted R&D, working capital, pursue US prescription market expansion opportunities and IPO costs. An IPO is planned for late November 2021 providing Pre-IPO investors a viable exit strategy.
An investment in Xerion gives investors exposure to established large global market opportunities in acne, fungal nail disease, atopic dermatitis, psoriasis and rosacea. These markets are estimated to be worth in excess of US$37B globally.
Xerion is an Australian based specialty pharmaceutical company focusing on key dermatological indications using its proprietary active ingredient, AMYCOT®. Xerion has a CONSUMER HEALTH division focusing on Over the Counter (OTC) sales in Australia and select international markets as well as a PRESCRIPTION division aimed at the lucrative USA market.
Xerion’s first product, nailKALM® is designed for the treatment of Onychomycosis (fungal nail disease) and is sold as an OTC product in Australia. The product is clinically proven and TGA listed to treat fungal nail disease. Chemist Warehouse is our largest Australian customer and have recently launched an exciting national TV campaign that showcases the unique benefits of nailKALM® – Chemist Warehouse nailKALM TVC – June 2021 . nailKALM® is also sold directly to podiatrists.
About Xerion Limited
Xerion is an Australian based specialty pharmaceutical company whose focus is to build a US prescription drug pipeline of 5 new products using AMYCOT® for key dermatological indications.
AMYCOT® is a powerful natural ingredient derived from a strain of spirulina (Arthrospira maxima). AMYCOT® has been shown to have excellent anti-inflammatory, anti-bacterial, anti-fungal and skin regenerative properties through extensive pre-clinical and clinical evidence. This proprietary technology is naturally derived, has no reported significant side effects and is cost effective to produce.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
